The amazing cN-II, the enzyme that keeps us busy

References

• Galmarini, C. M.; Jordheim, L.; Dumontet, C. Role of IMP-Selective 5’-Nucleotidase (cN-II) in Hematological Malignancies. Leuk. Lymphoma 2003, 44, 1105–1111.
   PubMed Web of Science ®Google Scholar
• Ipata, P. L.; Tozzi, M. G. Metabolic, Pathological, and Therapeutic Perspectives Intracellular 5’-Nucleotidases. Curr. Med. Chem. 2013, 20, 4203–4204.
   PubMed Web of Science ®Google Scholar
• Jordheim, L. P. Expanding the Clinical Relevance of the 5’-Nucleotidase cN-II/NT5C2. Purinergic Signal 2018, 14, 321–329. DOI: https://doi.org/10.1007/s11302-018-9627-2.
   PubMed Web of Science ®Google Scholar
• Jordheim, L. P.; Chaloin, L. Therapeutic Perspectives for cN-II in Cancer. Curr. Med. Chem. 2013, 20, 4292–4303.
   PubMed Web of Science ®Google Scholar
• Tozzi, M. G.; Pesi, R.; Allegrini, S. On the Physiological Role of Cytosolic 5’-Nucleotidase II (cN-II): Pathological and Therapeutical Implications. Curr. Med. Chem. 2013, 20, 4285–4291.
   PubMed Web of Science ®Google Scholar
• Dieck, C. L.; Ferrando, A. Genetics and Mechanisms of NT5C2-Driven Chemotherapy Resistance in Relapsed ALL. Blood 2019, 133, 2263–2268. DOI: https://doi.org/10.1182/blood-2019-01-852392.
   PubMed Web of Science ®Google Scholar
• Oka, J.; Matsumoto, A.; Hosokawa, Y.; Inoue, S. Molecular Cloning of Human Cytosolic Purine 5’-Nucleotidase. Biochem. Biophys. Res. Commun. 1994, 205, 917–922.
   PubMed Web of Science ®Google Scholar
• Wallden, K.; Stenmark, P.; Nyman, T.; Flodin, S.; Graslund, S.; Loppnau, P.; Bianchi, V.; Nordlund, P. Crystal Structure of Human Cytosolic 5’-Nucleotidase II: Insights into Allosteric Regulation and Substrate Recognition. J. Biol. Chem. 2007, 282, 17828–17836.
   PubMed Web of Science ®Google Scholar
• Pesi, R.; Allegrini, S.; Balestri, F.; Garcia-Gil, M.; Cividini, F.; Colombaioni, L.; Jordheim, L. P.; Camici, M.; Tozzi, M. G. Cytosolic 5’-Nucleotidase II is a Sensor of Energy Charge and Oxidative Stress: A Possible Function as Metabolic Regulator. Cells 2021, 10, E128. DOI: https://doi.org/10.3390/cells10010182.
   PubMed Web of Science ®Google Scholar
• Cividini, F.; Tozzi, M. G.; Galli, A.; Pesi, R.; Camici, M.; Dumontet, C.; Jordheim, L. P.; Allegrini, S. Cytosolic 5’-Nucleotidase II Interacts with the Leucin Rich Repeat of NLR Family Member Ipaf. PLoS One 2015, 10, e0121525.
   PubMed Web of Science ®Google Scholar
• Allegrini, S.; Filoni, D. N.; Galli, A.; Collavoli, A.; Pesi, R.; Camici, M.; Tozzi, M. G. Expression of Bovine Cytosolic 5’-Nucleotidase (cN-II) in Yeast: Nucleotide Pools Disturbance and Its Consequences on Growth and Homologous Recombination. PLoS One 2013, 8, e63914.
   PubMed Web of Science ®Google Scholar
• Cividini, F.; Filoni, D. N.; Pesi, R.; Allegrini, S.; Camici, M.; Tozzi, M. G. IMP-GMP Specific Cytosolic 5’-Nucleotidase Regulates Nucleotide Pool and Prodrug Metabolism. Biochim. Biophys. Acta 2015, 1850, 1354–1361.
   PubMed Web of Science ®Google Scholar
• Kviklyte, S.; Vertommen, D.; Yerna, X.; Andersen, H.; Xu, X.; Gailly, P.; Bohlooly, Y. M.; Oscarsson, J.; Rider, M. H. Effects of Genetic Deletion of Soluble 5′-Nucleotidases NT5C1A and NT5C2 on AMPK Activation and Nucleotide Levels in Contracting Mouse Skeletal Muscles. Am. J. Physiol. Endocrinol. Metab. 2017, 313, E48–E62.
   PubMed Web of Science ®Google Scholar
• Tzoneva, G.; Dieck, C. L.; Oshima, K.; Ambesi-Impiombato, A.; Sanchez-Martin, M.; Madubata, C. J.; Khiabanian, H.; Yu, J.; Waanders, E.; Iacobucci, I.; et al. Clonal Evolution Mechanisms in NT5C2 Mutant-Relapsed Acute Lymphoblastic Leukaemia. Nature 2018, 553, 511–514. DOI: https://doi.org/10.1038/nature25186.
   PubMed Web of Science ®Google Scholar
• Cadassou, O.; Raza, M. Z.; Machon, C.; Gudefin, L.; Armanet, C.; Chettab, K.; Guitton, J.; Tozzi, M. G.; Dumontet, C.; Cros-Perrial, E.; Jordheim, L. P. Enhanced Migration of Breast and Lung Cancer Cells Deficient for cN-II and CD73 via COX-2/PGE2/AKT Axis Regulation. Cell Oncol. (Dordr)) 2021, 44, 151–165. DOI: https://doi.org/10.1007/s13402-020-00558-w.
   PubMed Web of Science ®Google Scholar
• Pesi, R.; Petrotto, E.; Colombaioni, L.; Allegrini, S.; Garcia-Gil, M.; Camici, M.; Jordheim, L. P.; Tozzi, M. G. Cytosolic 5’-Nucleotidase II Silencing in a Human Lung Carcinoma Cell Line Opposes Cancer Phenotype with a Concomitant Increase in p53 Phosphorylation. Int. J. Mol. Sci. 2018, 19, 2115.
   Web of Science ®Google Scholar
• Kulkarni, S. S.; Karlsson, H. K.; Szekeres, F.; Chibalin, A. V.; Krook, A.; Zierath, J. R. Suppression of 5’-Nucleotidase Enzymes Promotes AMP-Activated Protein Kinase (AMPK) Phosphorylation and Metabolism in Human and Mouse Skeletal Muscle. J. Biol. Chem. 2011, 286, 34567–34574. DOI: https://doi.org/10.1074/jbc.M111.268292.
   PubMed Web of Science ®Google Scholar
• Johanns, M.; Kviklyte, S.; Chuang, S. J.; Corbeels, K.; Jacobs, R.; Herinckx, G.; Vertommen, D.; Schakman, O.; Duparc, T.; Cani, P. D.; et al. M.; Van Der Schueren B.; Oscarsson J.; Rider M. H. Genetic Deletion of Soluble 5’-Nucleotidase II Reduces Body Weight Gain and Insulin Resistance Induced by a High-Fat Diet. Mol. Genet. Metab. 2019, 126, 377–387. DOI: https://doi.org/10.1016/j.ymgme.2019.01.017.
   PubMed Web of Science ®Google Scholar
• Bricard, G.; Cadassou, O.; Cassagnes, L. E.; Cros-Perrial, E.; Payen-Gay, L.; Puy, J. Y.; Lefebvre-Tournier, I.; Tozzi, M. G.; Dumontet, C.; Jordheim, L. P. The Cytosolic 5’-Nucleotidase cN-II Lowers the Adaptability to Glucose Deprivation in Human Breast Cancer Cells. Oncotarget 2017, 8, 67380–67393.
   PubMedGoogle Scholar
• Cividini, F.; Cros-Perrial, E.; Pesi, R.; Machon, C.; Allegrini, S.; Camici, M.; Dumontet, C.; Jordheim, L. P.; Tozzi, M. G. Cell Proliferation and Drug Sensitivity of Human Glioblastoma Cells Are Altered by the Stable Modulation of Cytosolic 5’-Nucleotidase II. Int. J. Biochem. Cell Biol. 2015, 65, 222–229.
   PubMed Web of Science ®Google Scholar
• Bricard, G.; Cros-Perrial, E.; Machon, C.; Dumontet, C.; Jordheim, L. P. Stably Transfected Adherent Cancer Cell Models with Decreased Expression of 5’-Nucleotidase cN-II. Nucleosides Nucleotides Nucleic Acids 2016, 35, 604–612.
   PubMed Web of Science ®Google Scholar
• Jordheim, L. P.; Puy, J.-Y.; Cros-Perrial, E.; Peyrottes, S.; Lefebvre, I.; Périgaud, C.; Dumontet, C. Cros-Perrial E.; Peyrottes S.; Lefebvre I.; Perigaud C.; Dumontet C. Determination of the Enzymatic Activity of Cytosolic 5’-Nucleotidase cN-II in Cancer Cells: Development of a Simple Analytical Method and Related Cell Line Models. Anal. Bioanal. Chem. 2015, 407, 5747–5758. DOI: https://doi.org/10.1007/s00216-015-8757-4.
   PubMed Web of Science ®Google Scholar
• Meyer, J. A.; Wang, J.; Hogan, L. E.; Yang, J. J.; Dandekar, S.; Patel, J. P.; Tang, Z.; Zumbo, P.; Li, S.; Zavadil, J.; et al. Relapse-Specific Mutations in NT5C2 in Childhood Acute Lymphoblastic Leukemia. Nat. Genet. 2013, 45, 290–294.
   Google Scholar
• Tzoneva, G.; Perez-Garcia, A.; Carpenter, Z.; Khiabanian, H.; Tosello, V.; Allegretta, M.; Paietta, E.; Racevskis, J.; Rowe, J. M.; Tallman, M. S.; et al. Activating Mutations in the NT5C2 Nucleotidase Gene Drive Chemotherapy Resistance in Relapsed ALL. Nat. Med. 2013, 19, 368–371. DOI: https://doi.org/10.1038/nm.3078.
   PubMed Web of Science ®Google Scholar
• Hnizda, A.; Fabry, M.; Moriyama, T.; Pachl, P.; Kugler, M.; Brinsa, V.; Ascher, D. B.; Carroll, W. L.; Novak, P.; Zaliova, M.; et al. Veverka V. Relapsed Acute Lymphoblastic Leukemia-Specific Mutations in NT5C2 Cluster into Hotspots Driving Intersubunit Stimulation. Leukemia 2018, 32, 1393–1403. DOI: https://doi.org/10.1038/s41375-018-0073-5.
   PubMed Web of Science ®Google Scholar
• Dieck, C. L.; Tzoneva, G.; Forouhar, F.; Carpenter, Z.; Ambesi-Impiombato, A.; Sanchez-Martin, M.; Kirschner-Schwabe, R.; Lew, S.; Seetharaman, J.; Tong, L.; Ferrando, A. A. . Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia. Cancer Cell 2018, 34, 136–147. e6.
   PubMed Web of Science ®Google Scholar
• Guillon, R.; Rahimova, R.; Preeti; Egron, D.; Rouanet, S.; Dumontet, C.; Aghajari, N.; Jordheim, L. P. Chaloin L.; Peyrottes S. Lead Optimization and Biological Evaluation of Fragment-Based cN-II Inhibitors. Eur. J. Med. Chem. 2019, 168, 28–44.
   PubMed Web of Science ®Google Scholar
• Dursun, U.; Koroglu, C.; Kocasoy Orhan, E.; Ugur, S. A.; Tolun, A. Autosomal Recessive Spastic Paraplegia (SPG45) with Mental Retardation Maps to 10q24.3-q25.1. Neurogenetics 2009, 10, 325–331.
   PubMed Web of Science ®Google Scholar
• Duarte, R. R. R.; Bachtel, N. D.; Cotel, M. C.; Lee, S. H.; Selvackadunco, S.; Watson, I. A.; Hovsepian, G. A.; Troakes, C.; Breen, G. D.; Nixon, D. F.; et al. The Psychiatric Risk Gene NT5C2 Regulates Adenosine Monophosphate-Activated Protein Kinase Signaling and Protein Translation in Human Neural Progenitor Cells. Biol. Psychiatry 2019, 86, 120–130.
   PubMed Web of Science ®Google Scholar